We are live on ! Find out more
BCM

BML Capital Management Portfolio holdings

AUM $176M
1-Year Est. Return 123.21%
This Fund
S&P 500
This Quarter Est. Return
+11.58%
1 Year Est. Return
+123.21%
3 Year Est. Return
+348.91%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$176M
AUM Growth
+$20.3M
Cap. Flow
+$13.7M
Cap. Flow %
7.8%
Top 10 Hldgs %
93.29%
Holding
19
New
3
Increased
5
Reduced
3
Closed
1

Top Buys

Rank Stock Value
1
ENGN icon
enGene Therapeutics
ENGN
+$27.2M
2
KHC icon
Kraft Heinz
KHC
+$7.85M
3
OM icon
Outset Medical
OM
+$2.7M
4
KMX icon
CarMax
KMX
+$762K
5
CNTB
Connect Biopharma Holdings
CNTB
+$399K

Top Sells

Rank Stock Value
1
ACRS icon
Aclaris Therapeutics
ACRS
+$10.1M
2
ORMP icon
Oramed Pharmaceuticals
ORMP
+$9.16M
3
KZR
Kezar Life Sciences
KZR
+$5.35M
4
AVIR icon
Atea Pharmaceuticals
AVIR
+$529K

Sector Composition

Rank Sector Weight
1 Healthcare 80.13%
2 Consumer Discretionary 10.31%
3 Consumer Staples 9.02%
4 Miscellaneous 0.54%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ACRS icon
1
Aclaris Therapeutics
ACRS
$873M
$63.3M 35.98%
11,975,000
-2,275,000
-16% -$10.1M
AVIR icon
2
Atea Pharmaceuticals
AVIR
$468M
$32.3M 18.36%
6,952,330
-106,327
-2% -$529K
ENGN icon
3
enGene Therapeutics
ENGN
$121M
$11.5M 6.55%
+6,669,908
New +$27.2M
KHC icon
4
Kraft Heinz
KHC
$29.6B
$11M 6.24%
465,000
+340,000
+272% +$7.85M
OM icon
5
Outset Medical
OM
$67.7M
$10.9M 6.18%
2,519,701
+617,500
+32% +$2.7M
KMX icon
6
CarMax
KMX
$8.92B
$9.12M 5.18%
172,500
+17,500
+11% +$762K
TLYS icon
7
Tilly's
TLYS
$136M
$9.03M 5.13%
2,150,000
– –
PMVP icon
8
PMV Pharmaceuticals
PMVP
$70.6M
$7.14M 4.06%
5,330,000
+10,000
+0.2% +$12.8K
TIL icon
9
Instil Bio
TIL
$51.5M
$4.96M 2.82%
645,600
– –
TGT icon
10
Target
TGT
$74.4B
$4.9M 2.78%
37,500
– –
ORMP icon
11
Oramed Pharmaceuticals
ORMP
$204M
$4.17M 2.37%
866,269
-2,300,962
-73% -$9.16M
JANX icon
12
Janux Therapeutics
JANX
$1.21B
$2.38M 1.35%
154,961
– –
PLRX icon
13
Pliant Therapeutics
PLRX
$69.4M
$1.76M 1%
1,546,137
– –
CNTB
14
Connect Biopharma Holdings
CNTB
$123M
$1.36M 0.78%
573,287
+164,400
+40% +$399K
IMA
15
ImageneBio Inc
IMA
$56.1M
$1.18M 0.67%
200,730
– –
WMT icon
16
PUT
Walmart Inc
WMT
$855B
$386K 0.22%
335
– –
CORZ icon
17
PUT
Core Scientific
CORZ
$5.78B
$298K 0.17%
+800
New +$18.8K
TSLA icon
18
PUT
Tesla
TSLA
$1.39T
$270K 0.15%
+375
New +$149K
KZR
19
DELISTED
Kezar Life Sciences
KZR
– –
-720,787
Closed -$5.35M

Similar funds

LFA
Legend Financial Advisors Pittsburgh, Pennsylvania $176M AUM 57.06% 1-Year Est. Return
BMCM
Black Maple Capital Management Milwaukee, Wisconsin $176M AUM 9.49% 1-Year Est. Return
KRAVCF
Karnit Road Accident Victims Compensation Fund Tel-Aviv $176M AUM
CC
Caspian Capital New York $176M AUM
ADMI
Albert D. Mason Inc Boston, Massachusetts $176M AUM 40.3% 1-Year Est. Return
DF
Dedeker Financial St. Louis Park, Minnesota $176M AUM
OL
OneFund LLC Saint Petersburg, Florida $176M AUM 42.78% 1-Year Est. Return
MP
Marcho Partners London, United Kingdom $176M AUM 7.16% 1-Year Est. Return

BML Capital Management's Q2 2026 Portfolio in Review

As of Q2 2026, BML Capital Management held 19 positions worth $176M, up 13% from $156M the previous quarter. Its ten largest holdings account for 93% of the portfolio.

BML Capital Management deployed $13.7M of net new capital in Q2 2026, opening 3 new positions and adding to 5 existing holdings. Its largest new stake was enGene Therapeutics: 6,669,908 shares worth $11.5M.

By sector, the portfolio is most concentrated in Healthcare at 80% of assets, down from 85% a quarter earlier, followed by Consumer Discretionary and Consumer Staples.

On the sell side, the largest reduction was Aclaris Therapeutics, an estimated $10.1M trimmed.

  • BML Capital Management's largest Q2 2026 buy was enGene Therapeutics: 6,669,908 shares worth $11.5M.
  • BML Capital Management added most to Kraft Heinz in Q2 2026, an estimated $7.85M increase.
  • BML Capital Management's biggest Q2 2026 reduction was Aclaris Therapeutics, cutting an estimated $10.1M.
  • BML Capital Management fully exited Kezar Life Sciences in Q2 2026, selling an estimated $5.35M.
  • BML Capital Management's ten largest holdings make up 93% of its $176M portfolio in Q2 2026.
  • BML Capital Management opened 3 new positions and closed 1 in Q2 2026.
  • BML Capital Management's portfolio value rose 13% quarter-over-quarter to $176M.

Based on BML Capital Management's 13F filing for Q2 2026, filed 7 Aug 2026.